Investing.com - Viridian Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Viridian Therapeutics announced earnings per share of $-0.86 on revenue of $1.2M. Analysts polled by Investing.com anticipated EPS of $-0.98 on revenue of $303.33K.
Viridian Therapeutics shares are up 3.5% from the beginning of the year, still down 21.78% from its 52 week high of $26.22 set on August 17.
Viridian Therapeutics follows other major Healthcare sector earnings this month
Viridian Therapeutics's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar